FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599639743> ?p ?o ?g. }

• W2599639743 abstract "7086 Background: Cancer patients often experience comorbidities that may affect their therapeutic plan, prognosis, and outcome. Few studies have evaluated comorbidities in myelodysplastic syndromes (MDS). The aim of our study was to determine the effect of comorbidity on the survival of patients with MDS. Methods: We reviewed the medical records of consecutive adult MDS patients who presented to our comprehensive cancer center in 2002. The Adult Comorbidity Evaluation-27 (ACE-27), a validated 27-item comorbidity index for cancer patients, was used to assess the severity of comorbid conditions. For each patient, we obtained demographic data and specific staging information based on the International Prognostic Scoring System (IPSS). We also collected information on bone marrow transplantation (BMT), mortality and survival. Kaplan-Meier methods and log-rank tests were used to assess survival. Results: Of the 55 patients included in this preliminary report, 41 (74.5%) were male, and 47 (85.5%) were white; mean age was 66.4 years; mean follow-up 22.2 months. The three most common comorbidities were hypertension, diabetes mellitus, and coronary artery disease. A total of 90.9% of patients had an IPSS risk of intermediate or higher. The ACE-27 comorbidity scores were as follows: none, 18 patients (32.7%); mild, 17 (30.9%); moderate, 9 (16.4%); and severe, 11 (20.0%). Fifty patients (90.9%) died, whereas 9 (16.4%) underwent BMT. Median survival according to ACE-27 scores was: 22 months for patients with no comorbidity, 11 months for patients with mild or moderate comorbidity, and 8 months for those with severe comorbidity; this trend did not reach statistical significance (p = 0.42). A linear trend was observed between the severity of comorbidity and having received BMT: half of the patients with no comorbidities received BMT compared to none in the group with a severe score (p = 0.02). Conclusions: A small trend was observed between survival and comorbidity. Most of our patients had an advanced IPSS stage which may have decreased the strength of this association. Patients with comorbid conditions received BMT less often than those without comorbidity. Further studies are needed to evaluate the effects of comorbidities on the prognosis and therapeutic options of patients with early-stage MDS. No significant financial relationships to disclose." @default.
• W2599639743 created "2017-04-07" @default.
• W2599639743 creator A5030500582 @default.
• W2599639743 creator A5051073482 @default.
• W2599639743 creator A5061026876 @default.
• W2599639743 creator A5065216794 @default.
• W2599639743 creator A5083793750 @default.
• W2599639743 date "2009-05-20" @default.
• W2599639743 modified "2023-10-18" @default.
• W2599639743 title "Comorbidities and prognosis of myelodysplastic syndromes" @default.
• W2599639743 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.7086" @default.
• W2599639743 hasPublicationYear "2009" @default.
• W2599639743 type Work @default.
• W2599639743 sameAs 2599639743 @default.
• W2599639743 citedByCount "0" @default.
• W2599639743 crossrefType "journal-article" @default.
• W2599639743 hasAuthorship W2599639743A5030500582 @default.
• W2599639743 hasAuthorship W2599639743A5051073482 @default.
• W2599639743 hasAuthorship W2599639743A5061026876 @default.
• W2599639743 hasAuthorship W2599639743A5065216794 @default.
• W2599639743 hasAuthorship W2599639743A5083793750 @default.
• W2599639743 hasConcept C10515644 @default.
• W2599639743 hasConcept C121608353 @default.
• W2599639743 hasConcept C126322002 @default.
• W2599639743 hasConcept C143998085 @default.
• W2599639743 hasConcept C195910791 @default.
• W2599639743 hasConcept C2779159551 @default.
• W2599639743 hasConcept C2780007613 @default.
• W2599639743 hasConcept C2780240888 @default.
• W2599639743 hasConcept C2780817109 @default.
• W2599639743 hasConcept C71924100 @default.
• W2599639743 hasConceptScore W2599639743C10515644 @default.
• W2599639743 hasConceptScore W2599639743C121608353 @default.
• W2599639743 hasConceptScore W2599639743C126322002 @default.
• W2599639743 hasConceptScore W2599639743C143998085 @default.
• W2599639743 hasConceptScore W2599639743C195910791 @default.
• W2599639743 hasConceptScore W2599639743C2779159551 @default.
• W2599639743 hasConceptScore W2599639743C2780007613 @default.
• W2599639743 hasConceptScore W2599639743C2780240888 @default.
• W2599639743 hasConceptScore W2599639743C2780817109 @default.
• W2599639743 hasConceptScore W2599639743C71924100 @default.
• W2599639743 hasLocation W25996397431 @default.
• W2599639743 hasOpenAccess W2599639743 @default.
• W2599639743 hasPrimaryLocation W25996397431 @default.
• W2599639743 hasRelatedWork W1029553694 @default.
• W2599639743 hasRelatedWork W1530573014 @default.
• W2599639743 hasRelatedWork W1967378605 @default.
• W2599639743 hasRelatedWork W1977167963 @default.
• W2599639743 hasRelatedWork W1985579946 @default.
• W2599639743 hasRelatedWork W2040794645 @default.
• W2599639743 hasRelatedWork W2106428050 @default.
• W2599639743 hasRelatedWork W2114267013 @default.
• W2599639743 hasRelatedWork W2132853295 @default.
• W2599639743 hasRelatedWork W2183584641 @default.
• W2599639743 hasRelatedWork W2285470142 @default.
• W2599639743 hasRelatedWork W2552142435 @default.
• W2599639743 hasRelatedWork W2557336122 @default.
• W2599639743 hasRelatedWork W2567369862 @default.
• W2599639743 hasRelatedWork W2755661383 @default.
• W2599639743 hasRelatedWork W2771730530 @default.
• W2599639743 hasRelatedWork W2912756854 @default.
• W2599639743 hasRelatedWork W2976907750 @default.
• W2599639743 hasRelatedWork W2993594890 @default.
• W2599639743 hasRelatedWork W3142623810 @default.
• W2599639743 isParatext "false" @default.
• W2599639743 isRetracted "false" @default.
• W2599639743 magId "2599639743" @default.
• W2599639743 workType "article" @default.